MAPT and Alzheimer disease: It has previously been shown that the Aβ and tau PMCA/RT–QuIC may work in diagnosing AD by distinguising between AD patients and other neurodegenerative disorders or controls by protein misfolding cyclic amplification assay (Ab-PMCA) with more than 90% of sensitivity and specificity using cerebrospinal fluid [58].